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Abstract 
Obesity-related changes in the composition of the body interfere with the proper functioning of the thyrotropic axis, leading to its dis-
turbances and changes in the structure of the thyroid gland. Distinguishing what is related to obesity and what constitutes pathological 
changes is crucial for the proper treatment of patients.
In this paper authors present a case of a patient with a diet-induced obesity, whose only abnormalities in thyroid assessment included 
an elevated level of thyroid stimulating hormone (TSH) and hypoechoic thyroid gland on ultrasound. Based on this clinical situation, we 
reviewed literature in order to establish rules regarding management of thyroid disorders in obese individuals. 
The most common obesity-related thyroid abnormality is an isolated increase of TSH, without clinical symptoms of hypothyroidism, 
defined as hyperthyrotropinaemia. In obese adults, autoimmune thyroid disease is found equally often as in the normal-weight popula-
tion. Thyroid enlargement, increased risk of nodules, and decreased echogenicity, not related to autoimmunity, is frequent among obese 
individuals. Weight loss leads to the normalisation of TSH levels and thyroid echogenicity. 
Excessive weight can influence both the TSH level and ultrasound image of the thyroid gland; however, these findings can be reversed 
by weight reduction. Therefore, in asymptomatic obese patients elevated TSH should not be treated with thyroid hormone replacement. 
(Endokrynol Pol 2019; 70 (3): 270–276)
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Introduction
Lifestyle and dietary changes over the past decades 
have led to the currently prevailing pandemic of obe-
sity. According to the WHO reports from 2016, around 
39% of the world’s population are overweight (body 
mass index [BMI] > 25) and 13% are obese (BMI > 30). 
The growing number of obese individuals is a serious 
problem for the health care system because obesity 
contributes to increased mortality and disability, directly 
and indirectly, due to the number of associated com-
plications affecting practically every organ and system 
in the human body.
Obesity-related changes in the composition of the 
body, hormonal activity, and cytokine profile interfere 
with proper functioning of the thyrotropic axis, lead-
ing to its disturbances and changes in the structure of 
the thyroid gland [2]. However, data published so far 
do not allow us to state clearly whether these changes 
are permanent or temporary and disappear after 
weight reduction. Given the increasing prevalence of 
obesity, an interpretation of the thyroid function tests 
in obese patients is nowadays an everyday challenge 
in clinical practice. Distinguishing what is related to 
obesity and what constitutes pathological changes is 
crucial for the proper treatment of patients. Recently, 
an excellent review regarding the pathophysiology 
of obesity-associated changes in thyroid function has 
been published [2]. In this paper, we intend to focus on 
more clinical aspects of this problem that may be useful 
in daily practice.
Clinical situation
A 51-year-old woman presented with a 30-year-long his-
tory of difficulties with maintaining proper body weight 
despite being physically active and eating a healthy 
diet. Her medical history revealed type 2 diabetes (di-
agnosed 10 years before and treated with metformin), 
hypertriglyceridaemia, and hypercholesterolaemia 
treated with a statin. Her family history was remark-
able for metabolic diseases (obesity and diabetes). Her 
physical examination, apart from obesity (body mass 
index, BMI = 36), did not show other abnormal find-
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the normal range and her anti-thyroid autoantibodies 
concentrations were within the normal range.
Her thyroid ultrasound revealed diffusely, mildly 
hypoechoic gland without distinctive nodules. Right 
lobe measurements in mm: 16 × 13 × 45 and left lobe 
16 × 12 × 14. No pathological lymph nodes were found 
(Fig. 2A, B). 
Clinical question: How should the patient’s thyroid func-
tion tests and thyroid ultrasound be further enhanced?
How often can we expect thyroid 
dysfunction in obese individuals?
According to available epidemiological studies, the 
majority of obese patients without diagnosed thyroid 
disease remain euthyroid [3]. However, numerous 
studies showed a direct proportional relationship be-
tween TSH concentration and BMI, and subsequently 
it was found that up to 20% of obese patients present 
with subclinical hypothyroidism (SH, characterised by 
elevated TSH level, while free thyroid hormone con-
centrations are within normal limits) [3–5]. To compare, 
subclinical hypothyroidism affects approximately 4–9% 
of patients with normal body weight [6]. The prevalence 
of subclinical hypothyroidism in different populations 
of obese individuals is summarised in Table II. 
The pathogenesis of obesity-related changes in 
thyroid hormone levels has recently been explained in 
detail by Garcia-Solis et al. [2]. In short, an increase in 
TSH level in obese individuals is believed to result from 
the central resistance to locally-produced triiodothyro-
nine (fT3) and represents an adaptive process aimed at 
increasing basal energy expenditure.
Another possible explanation is the effect of high 
concentrations of leptin (adipokine produced by adi-
pose tissue), the levels of which correlate positively with 
TSH, regardless of BMI [7]. Experimental data showed 
ings including features of hypercortisolaemia, hyper-
androgenism, or hypothyroidism (Fig. 1A–D).
Her laboratory findings are summarised in Ta-
ble I (abnormal results are in bold). The only abnormal-
ity found in the endocrinological tests was a slightly 
elevated level of thyroid stimulating hormone (TSH), 
while levels of the free thyroid hormones were within 
Table I. Laboratory findings
Parameter Normal range Results
White blood count [103/uL] 4–11 6.24
Red blood count [103/uL] 3.8–5.2 4.62
Hemoglobin [g/dL] 12.0–16.0 12.4
Platelets [103/uL] 150–400 263
Thyroid stimulating hormone 
[uIU/mL] 0.23–4.2 4.8
Free triiodothyronine [pmol/L] 3.1–6.8 3.93
Free thyroxine [pmol/L] 11–22 18.7
Thyroperoxidase  
antibodies [uIU/mL] < 34 < 0.9
Thyroglobulin  
antibodies [uIU/mL] < 115 33.9
Cortisol after 1 mg 
of dexamethasone [ug/dL] < 1.8 0.52
Sodium [mmol/L] 137–145 135.4
Potassium [mmol/L] 3.6–5.0 4.38
Alanine transaminase [U/L] 7–56 12
Glucose [mg%] 70–99 115
Insulin [uIU/mL] 2.6–24.9 15.0
HOMA-IR < 2 4.26
HbA1c (%) < 7.0 7.2
Triglycerides [mg/dL] 50–150 342
Total cholesterol [mg/dL] 120–190 131
HOMA-IR — HOmeostatic Model Assesment-Insulin Resistance
Figure 1. Clinical presentation of the patient
a
b C d
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that leptin could directly stimulate thyrotropin-releas-
ing hormone (TRH) and TSH secretion [8]. Furthermore, 
leptin is responsible for the increase in fT4 to fT3 con-
version, by activation of deiodinases, which is believed 
to constitute another mechanism that increases the 
basic metabolic rate and energy expenditure [9]. Both 
leptin and TSH levels decrease after calorie restriction, 
which may suggest that energy-balance status more 
than adiposity itself affect thyrotropic hormone release. 
Hypothetically, positive energy-balance might increase 
TSH, which leads to thyroid hormone elevation and 
therefore thermogenesis along with energy expendi-
ture, so further weight gain is limited [3, 7]. 
Jansen et al. suggest that hyperthyrotropinaemia is 
a more adequate name than subclinical hypothyroidism 
to describe obesity-related TSH elevation [10]. The increase 
of TSH observed in obese patients represents the central 
axis activation in order to boost energy expenditure to 
prevent weight gain. In true SH free thyroid hormone 
levels are usually low/normal, while among obese they 
are found to be in normal and high/normal range, which 
reflects central hypothalamus and pituitary resistance 
[10]. Indeed, experimental studies suggest that obesity 
is associated with lower expression of thyroid hormone 
receptors (TR) as well as deiodinases both in the central 
nervous system and in peripheral tissues [2, 11, 12]. 
Central and peripheral resistance to thyroid hormones 
observed in obese subjects can also be explained by the 
theory of metabolic inflammation (“metaflammation”). 
This term describes a chronic inflammatory state that 
occurs among obese patients and affects many tis-
sues. According to this theory, excess lipid accumulation 
in adipose tissue leads to increased expression of genes 
encoding chemokines, cytokines, and adhesion molecules 
in adipocytes, which draws immune cells, which in turn 
leads to the production of inflammatory mediators [2, 13].
Although hyperthyrotropinaemia is more common, 
obesity does not exclude a diagnosis of hyperthyroid-
ism. One should also remember that decreased TSH 
level in an obese subject may suggest hypothalamic 
dysfunction. However, detailed data on those phenom-
ena are sparse.
Figure 2. Thyroid USG images: longitudinal (A) and transverse (B) view
a b
Table II. Prevalence of subclinical hypothyroidism in different populations of obese individuals
Study [ref.]
Number 
of study 
participants
Prevalence 
of SH  
(%)
Mean TSH 
[uIU/mL]
Mean fT3 
[pmol/L]
Mean fT4 
[pmol/L]
Positive 
aTPO  
(%)
Positive aTG 
(%)
Chikunguwo S et al. [5] 
Bétry C et al. [7]
86 
800
10.5 
20
4.5 
2.8
Janssen IMC et al. [10] 503 14.1 5.8  (among SH)
15.2 
(among SH)
Rotondi M et al. [14] 350 13.7 5.95 (among SH)
3.06  
(among SH)
11.41  
(among SH) 10 5.1
Rotondi M et al [15] 
García-García E et al. [16]
55 
129
5.4 
3.12 3.2
11.4 
16.3 27.3 18.2
Bhowmick SK et al. [17] 308 11.7 2.51 17.8
Marzullo P et al. [20]  
Moulin de Moraes CM et al. [24]
165 
72
10.3 
18
2.7 
3.03 2.8
11.7 
13.4 17 15.2
Abu-Ghanem Y et al. [25] 38 2.45 13.27
SH — subclinical hypothyroidism; TSH — thyroid stimulating hormone; fT3 — free triiodothyronine; fT4 — free thyroxine; aTPO — thyroperoxidase antibodies;  
aTG — thyroglobulin antibodies
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In summary, most obese individuals are euthyroid. 
The most common obesity-associated thyroid hormone 
abnormality is hyperthyrotropinaemia, which can be 
distinguished from SH by normal and/or high/normal 
concentrations of thyroid hormones.  
Does obesity increase the risk of AITD?
Epidemiological studies show that adult obese patients 
with elevated levels of TSH have significantly (up to 
50%) lower rates of antithyroid antibodies (thyroperoxi-
dase antibodies — aTPO and thyroglobulin antibodies 
— aTG) compared to patients with normal body weight 
with similarly elevated levels of TSH. In one study, 
untreated obese patients with TSH levels above the 
normal range had half the rate of antithyroid antibodies 
incidence when compared to normal-weight individuals 
(32% vs. 66%) [15]. Antibodies in euthyroid individuals 
in obese and non-obese patient groups were found simi-
larly often (in about 11% of people). These data suggest 
that the autoimmune process is not the main cause of 
elevated levels of TSH among adult obese patients [15].
In turn, in a paediatric population, Garcia et al. 
showed that thyroid autoimmunity occurred more often 
(6.3% vs. 2.9%) in overweight children and adolescents 
in comparison to normal weight paediatric patients 
[16]. A similar observation was found among 308 obese 
children in a study conducted by Bhowmick et al. [17]. 
There are a number of theories regarding immune 
system dysfunction that may lead to autoimmunity 
in obese subjects. That includes vitamin D deficiency 
associated with obesity [18]. Similarly, metabolic in-
flammation may occur because high levels of pro-in-
flammatory cytokines correlate positively with higher 
concentrations of antithyroid antibodies [19]. Finally, 
high leptin levels may affect the occurrence of autoim-
mune thyroid disease both directly and by promoting 
pro-inflammatory state [20]. 
In summary, in adult obese individuals the preva-
lence of thyroid autoimmunity (assessed by the pres-
ence of antithyroid antibodies) does not differ from the 
normal-weight population even in those with elevated 
TSH levels. In contrast, in a study performed in paedi-
atric obese patients, antithyroid autoantibodies were 
found significantly more often than in normal-weight 
peers [21]. The prevalence of elevated aTPO and aTG 
levels in obese subjects in different populations is sum-
marised in Table II.  
Does obesity influence ultrasound imaging  
of the thyroid gland?
Literature data indicate that patients with obesity are 
more likely to present hypoechoic images of thyroid 
parenchyma in ultrasound study (US), which is con-
sidered a characteristic marker of autoimmune thy-
roiditis (AITD). However, the presence of antithyroid 
antibodies in different populations of obese individuals 
does not correlate with the presence of changes in the 
echogenicity of the thyroid gland. In one of the few 
studies, correlation of the ultrasound image with auto-
immune thyroiditis was observed in only 20.9% of obese 
people vs. 85.7% of people in the normal-weight group 
[15]. A hypoechogenic thyroid on US with absence of 
antithyroid antibodies was observed in only 1.9% of 
non-obese individuals, compared to 64.8% of obese 
patients [15]. This indicates that the hypoechoic nature 
of the thyroid parenchyma in obese patients must be 
due to other reasons than the autoimmune process. 
Metabolic inflammation is again believed to be a pos-
sible explanation of this US phenomenon. The cytokines 
released by adipose tissue lead to vasodilation and more 
permeable blood vessels in the thyroid. As a result, 
plasma exudation and imbibition of parenchyma occur. 
This situation differs from the autoimmune thyroiditis 
that was confirmed by a fine-needle biopsy, which did 
not show lymphocyte infiltrations, ruling out Hashi-
moto’s disease as a cause of parenchyma derangement 
[21]. It is also suggested that the hypoechogenic image 
of the thyroid gland in obese subjects may result from 
the accumulation of adipose tissue [15]. 
Because TSH levels increase in parallel with BMI 
value, and TSH is the main tropic factor for the thyreo-
cytes, one should also remember that obesity is associ-
ated with increased thyroid volume and an increased 
risk of thyroid nodules [3, 22]. 
To sum up: obesity is associated with several changes 
in thyroid US, including its enlargement, increased risk 
of nodules and decreased echogenicity, which does not 
mirror the presence of autoimmune thyroid disease. 
Does weight loss have an influence 
on thyroid function and US imaging?
Weight loss can be achieved by lifestyle interventions, 
pharmacological treatment, bariatric procedures, or 
a combination of them all. In studies based on lifestyle 
intervention (diet combined with increased physical 
activity), a decrease of fat mass was associated with 
a decrease in TSH level (from the mean 2.8 mU/L to 
2.2 mU/L) [23]. In this study, the number of individu-
als with TSH level above the normal range decreased 
significantly after the intervention from 17.2% to 6.2%. 
Available results indicate that bariatric surgery, regard-
less of the method, also results in a reduction of TSH 
to the normal range in nearly all patients. One study 
showed a mean reduction of TSH level from 4.5 to 1.9 
U/mL after the bariatric procedure (gastric bypass or 
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adjustable gastric banding), and all patients diagnosed 
with subclinical hypothyroidism before the procedure 
(10.5% of the studied group) experienced a normali-
sation of TSH levels. It is worth mentioning that fT4 
level was independent of BMI, and bariatric surgery 
did not affect this parameter [5]. Similar results were 
obtained Moraes et al. — in his group also all patients 
with subclinical hypothyroidism before the operation 
(25% of the group) experienced a normalisation of TSH 
after Roux-en-Y gastric bypass surgery [24]. In other 
studies the percentage of obese subjects whose TSH 
levels normalised after the procedure (laparoscopic 
sleeve gastrectomy) was as much as 90% [10, 25]. These 
findings strongly suggest that obesity-associated hyper-
thyrotropinaemia is transient and resolves after weight 
loss. The influence of surgery-induced weight loss on 
thyroid function in different studies is summarised in 
Table III.
In a study carried out in just 10 patients, which as-
sessed the influence of bariatric surgery on thyroid US, 
loss of weight was associated with a parallel increase in 
the thyroid echogenicity, suggesting that also morpho-
logical changes of the thyroid in obesity are reversible 
with weight loss [26].
In summary: available data strongly indicate that 
loss of weight leads to the normalisation of TSH lev-
els. So far, no large-scale study has shown how the 
echogenicity of the thyroid parenchyma changes after 
weight loss and whether there is a correlation with the 
ultrasound image and the incidence of autoimmune 
thyroid disease before and after weight loss. 
Should we treat thyroid dysfunction 
in obesity?
Administration of thyroid hormones to obese individu-
als to induce weight lost has been considered for a long 
time, and the first attempts were made in the 1940s and 
1950s [27]. This concept was based on the observation 
of hyperthyroid patients who, in the course of the 
disease, decrease their body weight by 15% on aver-
age, which is related to the thermogenic and lipolytic 
activity of thyroid hormones in adipose tissue. Thyroid 
hormones, in supraphysiological doses, has been ad-
ministered to euthyroid obese subjects during caloric 
deprivation to enhance weight loss [28]. However, such 
therapy resulted in muscle wasting and weakness and 
adverse cardiac effects due to subclinical or overt hy-
perthyroidism [29]. In contrast, physiological doses of 
thyroid hormones (5–20 µg of T3) as supplementation to 
a very low-calorie diet did not seem to be erosive for the 
muscle tissue and had a beneficial effect on lipid profile, 
without a significant influence on body weight [30, 31]. 
In his review from 2001 Krotkiewski listed clinical indi-
cations for the administration of thyroid hormones in 
obese individuals. The main indication for the use of LT4 
was subclinical hypothyroidism with hyperlipidaemia. 
Addition of T3 could have been considered in the case 
of patients with adequately substituted hypothyroid-
ism (regardless of its aetiology) with obesity resistant to 
a lifestyle intervention or suspected of thyroid hormone 
conversion disorders [27]. However, in a meta-analysis 
from 2009, Kaptein found that available data were insuf-
ficient to assess how thyroid hormone administration 
influences fat and muscle loss in obese subjects during 
caloric deprivation, and considering the risk of hyper-
thyroidism he discourages such therapy in euthyroid 
patients [29]. 
Because the lipid-lowering effect of thyroid hormone 
is mediated mainly by the thyroid hormone receptor 
(TR) b in the liver (while the effect on bone and heart 
mainly by TRa isoforms), selective TRb agonists may 
be effective for obesity-associated hyperlipidaemia [32]. 
However, weight loss with thyroid hormone analogue 
treatment has not yet been reported in clinical trials, 
and animal studies suggest that the regulation of basal 
metabolic rate is more dependent on TRa. Moreover, 
basic studies have demonstrated that adipose tissues of 
obese individuals are characterised by lower expression 
of genes encoding TR, which may limit the thermogenic 
Table III. The influence of weight loss on thyroid function
Study [ref.]
Number 
of study 
participants
Mean TSH  
[uIU/mL]
Mean fT4  
[pmol/L] BMI
Before After Before After Before After
Radetti G et al. [23] 72 2.8 2.2* 10.8 10.07 NS NS
Chikunguwo S et al. [5] 
Janssen IMC et al. [10]
86 
61
4.5 
5.8
1.9* 
2.8 15.2 13.9
49 
47
32 
33
Abu-Ghanem Y et al. [25] 38 2.45 1.82* 13.27 12.96 42.4 32.5*
Moulin de Moraes CM et al. [24] 72 3.03 1.97* 1.04 1.07 53 33.7*
Zendel A et al. [39] 72 3.9 3* 13.7 14.9 43.7 29.8*
TSH — thyroid stimulating hormone; fT4 — free thyroxine; BMI — body mass index; NS — not significant; *statistically significant difference
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and lipolytic potential of thyroid hormones and their 
derivates [11].
While there are no data justifying the administra-
tion of thyroid hormones to obese individuals with 
normal serum TSH levels, treatment of obese patients 
with elevated TSH requires an individual approach. If 
elevated TSH is the only abnormality, it can be defined 
as obesity-associated hyperthyrotropinaemia. This 
clinical condition is defined as an isolated increase 
of TSH (above the upper range but < 10 mlU/L) 
without clinical symptoms, thyroid antibodies, goi-
tre, or associated thyroidal illness. As was described 
above, in obese individuals hyperthyrotropinaemia 
represents an adaptive process aimed at increasing 
basal energy expenditure, and it may normalise after 
weight loss. Moreover, until now, no randomised, 
controlled trial evaluating the effectiveness of thyroid 
hormone treatment in obese adult individuals with 
hyperthyrotropinaemia or systematic review has been 
performed. The only trials regarding LT4 treatment of 
obese individuals with hyperthyrotropinaemia were 
performed in children. This concept was based on epi-
demiological data showing that in children increasing 
TSH is associated with impaired glucose metabolism 
and dyslipidaemia [33].
However, in children with the addition of thyroxine 
1–2 ug/kg for up to six months, lifestyle intervention 
did not cause a significant change in body weight, BMI, 
linear growth, or lipid profile [34, 35]. In obese children 
with hyperthyrotropinaemia dietary-behavioural 
intervention contributed to a reduction of body mass 
index, irrespective of levothyroxine use. This finding 
suggests that moderately elevated levels of TSH are 
a consequence rather than a cause of overweight and 
pharmacological treatment should be avoided. Given 
the fact that there is no evidence for a favourable effect 
of LT4 treatment on body weight in obese subjects with 
TSH < 10 mU/L and normal fT4 level, the American 
Thyroid Association guidelines do not recommend 
such treatment [36]. 
However, some obese individuals with increased 
TSH level < 10 mlU/L may meet the diagnostic 
criteria for mild subclinical hypothyroidism (e.g. 
showing symptoms of hypothyroidism, with thyroid 
hormone levels in the low-normal range or present 
antithyroid antibodies), and then some indications 
for LT4 supplementation occur. A typical situation is 
the procreation period in women and pregnancy [37]. 
Other indications for SH treatment refer to metabolic 
risk. There are data confirming that LT4 treatment in 
normal-weight patients with SH can reduce the levels 
of total and LDL cholesterol [36]. However, this effect 
is more pronounced in patients with TSH > 10 mU/L. 
What is important, while in euthyroid normal-weight 
patients FT4 levels are negatively correlated with TG, 
and TSH levels are correlated positively to total choles-
terol levels, in overweight subjects such a correlation 
does not exist. This finding indicates that body weight 
might interfere with the effect of thyroid hormone on 
lipid profile and LT4 treatment of obese patients with 
SH, and hyperlipidaemia may not be beneficial [38]. 
Moreover, levothyroxine replacement therapy for 
subclinical hypothyroidism did not result in improved 
survival or decreased cardiovascular morbidity. Data 
on health-related quality of life and symptoms did not 
demonstrate significant differences between interven-
tion groups [6].
In summary: patients with isolated hyperthyrotro-
pinaemia should not be treated with thyroid hormone 
replacement unless there are symptoms or other signs 
of thyroid disease. 
Final remarks and conclusions
The lack of prospective, case-control studies regarding 
the treatment of obesity-associated thyroid abnormali-
ties makes it impossible to formulate definite guidelines 
regarding their management in everyday practice. 
However, based on the available data, we can conclude 
that most obese patients are euthyroid, even though 
their TSH levels usually exceed those observed in 
normal-weight individuals. The most common thyroid 
hormone abnormality associated with obesity is hyper-
thyrotropinaemia, which can be distinguished from the 
SH by the normal and/or high/normal concentrations 
of thyroid hormones. Obesity is also associated with 
thyroid enlargement, increased risk of nodules, and 
decreased echogenicity in US imaging. However, the 
prevalence of antithyroid antibodies in adult obese 
patients is no higher than in the normal-weight popu-
lation.
Indications for LT4 treatment in obese individuals 
are limited to overt hypothyroidism and some selected 
cases of its subclinical form. Patients with isolated hy-
perthyrotropinaemia (such as the one presented in this 
paper) should not be treated with thyroid hormone 
replacement unless there are symptoms or other signs 
of thyroid disease. Administration of thyroid hormones 
to obese individuals without thyroid disease in order to 
induce weight reduction or improve metabolic profile 
is not justified and may lead to hyperthyroidism and 
its complications. 
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